{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Treatment-induced ADA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Treatment boosted ADA"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"ADA were categorized as: treatment induced, and treatment boosted response. Treatment-induced ADA: ADA that developed at any time during the ADA on-study observation period in participants without preexisting ADA (ADA that was present in samples drawn during the ADA pretreatment period). Treatment boosted ADA: Preexisting ADA with an increase in titer value between pretreatment \\& posttreatment samples of at least two titer steps, during the ADA on-study observation period.","groups":[{"description":"Participants received Isatuximab 20 mg/kg IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 248 weeks).","id":"OG000","title":"Phase 2: Isatuximab 20 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis was performed on ADA population which included all participants that received isatuximab in Phase 2 part of the study, with at least one ADA assessment reportable during the ADA on-study observation periods.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug up to 30 days after last study drug administration (maximum duration of exposure: up to 248 weeks)","title":"Phase 2: Number of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab","type":"SECONDARY","unitOfMeasure":"Participants"}